Comparative characteristics of application of statins in combination with fibrates and omega-3 polyunsaturated fatty acids in patients with coronary heart disease and type 2 diabetes mellitus
Keywords:coronary heart disease, type 2 diabetes mellitus, statins, fibrates, omega-3 polyunsaturated fatty acids
The comparative characteristic of application of statins in combination with fibrates and omega-3 polyunsaturated fatty acids in patients with coronary heart disease and type 2 diabetes mellitus were hold in the article. The study included 75 patients with CHD and type 2 diabetes mellitus, who were divided into two subgroups depending on the received lipid-lowering therapy. The first subgroup included 37 patients with coronary heart disease and concomitant type 2 diabetes mellitus, who in order to low the lipid level received atorvastatin in dose of 20 mg per day and fenofibrate at a dose of 14 mg per day after dinner. The second subgroup included 38 patients with the same nosological units who received atorvastatin in dose of 20 mg / day and omega-3 polyunsaturated fatty acids at a dose of 1000 mg in the morning and in the evening. The study demonstrated a positive effect of combinations of lipid-lowering therapy on lipid metabolism in the form of atorvastatin with fibrates and omega-3 polyunsaturated fatty acids in patients with coronary heart disease and type 2 diabetes mellitus due to the reduction of atherogenic fractions and increase of proatherogenic ones. According to the results of our study any significant differences of lipidogram depending on the lipid-lowering therapy schemes (atorvastatin and fibrates; atorvastatin and omega-3 polyunsaturated fatty acids) in patients with coronary artery disease and type 2 diabetes mellitus has not been established, but there was a trend to increase the level of HDL cholesterol in patients treated with omega-3 polyunsaturated fatty acids in addition to statin and to reduce TG in patients treated with fibrates in combination with statins.
Betteridge DJ. Nat Rev Cardiol 2011; 8:278-290. https://doi.org/10.1038/nrcardio.2011.23
Grundy S, Cleeman J, Merz C, et al. Circulation 2004;110:227-239. https://doi.org/10.1161/01.CIR.0000151100.28000.B3
Halle M, Berg A, Baumstark MW, et al. Atherosclerosis 2007; 143(1):185-192. https://doi.org/10.1016/S0021-91509800278-0
Amosova EN. Cerce i Sudyny 2011; 1:6-19.
Baigent C, et al. Lancet 2005; 366(9493):1267-1278. https://doi.org/10.1016/S0140-67360567394-1
Brugts JJ, Yetgin T, Hoeks SE, et al. BMJ 2009; 338:2376. https://doi.org/10.1136/bmj.b2376
Taylor F, Ward K, Moore THM, et al. Coch Database of Systematic Rev 2011; 1:Art. N CD004816.
The ACCORD Study Group. N Engl J Med 2010; 362:1563-1574. https://doi.org/10.1056/NEJMoa1001282
LaRosa JC, Grundy SM, Waters DD, et al. N Engl J Med 2005; 352:1425-1435. https://doi.org/10.1056/NEJMoa050461
Bagrij AJe. Novosti Mediciny i Farmacii 2010, available at: http://www.mif-ua.com/archive/article/15045.
Zhuravljova LV, Il’chenko IA, Lopina NA. Ukr Terapevt Zhurn 2012; 2:47-52.
Gerstein HC, Bosch J, Dagenais GR, et al. N Engl J Med 2012; 367:309-318. https://doi.org/10.1056/NEJMoa1203859
Kim SH, Kim MK, Lee HY, et al. Eur J Clin Nutr 2011; 65:110-116. https://doi.org/10.1038/ejcn.2011.120
Stacenko ME, Turkina SV, Inina LI. Volgogradskij Nauchno-Medicinskij Zhurnal 2012; 3:27-30.